Press releases

Oxford BioMedica to Present at 3rd Annual Regen Med Investor Day

London, UK – 20 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief Development Officer, will present at the 3rd Annual Regen Med Investor Day, being held Wednesday, March 25, 2015 in New York City.

Dr. Blake will present at 2:40pm ET / 6.40pm GMT to attending investors. During his presentation Dr. Blake will discuss Oxford BioMedica’s expertise in the clinical development and manufacturing of gene and cell therapies.

Details of the Oxford BioMedica presentation are as follows:

Event: ARM’s Regen Med Investor Day

Date: March 25, 2015

Time: 2.40pm ET / 6.40pm GMT

Location: Metropolitan Club, One East 60th Street, New York, NY 10022

At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcastand will be published on the event’s website shortly after the conference as well as on the company’s website in the media section: http://www.oxfordbiomedica.co.uk/webcasts-and-audio/.

- Ends -

Notes to editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications – Media Enquiries

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips

Tel: +44 (0)20 3709 5700